Return to Clinical Trials Search Results

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

Primary Outcome Measures : Part 1: To determine the navtemadlin Phase 3 dose [ Time Frame: 12 months ] Safety review committee (SRC) will determine the navtemadlin Phase 3 dose for Part 2 based on safety data from Part 1 Part 2: To compare progression-free (PFS) survival by independent review committee (IRC) between navtemadlin and placebo [ Time Frame: 50 months ] PFS defined as the time from randomization to disease progression by IRC or death, whichever occurs first



Recruitment Status

Current Studies